Users Coming Off Weight-Loss Jabs Gain Back Weight at a Quadrupled Rate Compared to Dieters

Fresh analysis indicates that people who discontinue popular weight-loss injections like Mounjaro or Wegovy can put back on reduced body mass at a significantly accelerated pace than those who end conventional diet and exercise programs.

Published data in a leading health publication demonstrates that while obese individuals frequently drop about a fifth of their body weight while using the jabs, the mass comes back at an average rate of 0.8 kg per month once they quit.

"Individuals using such drugs must be informed of the potential of quick weight regain when the treatment ends," warns expert Dr. Susan Jebb.

This pace of regain implies a return to pre-treatment mass within about one and a half years.

Analyzing Therapies

The study, which looked at 37 of studies involving over 9,000 of participants, contrasted the effects of GLP-1 agonists with other pills.

Scientists point out that people who shed pounds through diet and exercise usually experience a less rapid weight regain—perhaps 100 grams monthly—post-intervention.

Explaining the Fast Regain

Nutrition scientists believe the mechanism of the injections explains the heightened rebound.

GLP-1 drugs copy a natural hormone called GLP-1, which moderates hunger.

"Long-term administration of GLP-1 levels several times higher than normal might result in the system to generate a reduced amount of its own natural hormone, and may also diminish responsiveness to its actions," said Dr. Adam Collins, a dietetics specialist.

"Discontinuation of this GLP-1 'fix' results in hunger is no longer kept in check, making overeating a significant risk."

An Ongoing Condition?

The NHS recommend the injections for individuals with weight-linked health risks, accompanied by prescribed lifestyle changes.

Professionals contend that, considering the significant potential of weight regain, the therapy might need to be life-long.

This perspective is supported by pharmaceutical companies, who say that the results "highlight the chronic character of excess weight," similar to managing conditions like hypertension.

Patient Accounts

Individuals who have stopped the medication report a sudden return of appetite.

"I experienced a switch flipping and you become ravenous," described an individual.

This challenge is exacerbated if individuals have not developed sustainable dietary or behavioural changes during therapy.

Significant Interest

Survey data indicate that millions of people in the UK have used weight-loss jabs in the last 12 months, with desire remaining high.

• Adoption is greater among females compared to men.
• The middle-aged age group shows the greatest usage rates.
• A large proportion access the drugs through private healthcare rather than public health services.

Finally, researchers caution that while GLP-1 drugs are powerful tools for shedding pounds, they are not a standalone solution and lasting health benefits likely depends on ongoing behavioural changes.